Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00109239
Recruitment Status : Completed
First Posted : April 26, 2005
Last Update Posted : June 18, 2014
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Tracking Information
First Submitted Date  ICMJE April 26, 2005
First Posted Date  ICMJE April 26, 2005
Last Update Posted Date June 18, 2014
Study Start Date  ICMJE November 2000
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Official Title  ICMJE A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer
Brief Summary This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with capecitabine compared with capecitabine alone in subjects with previously treated metastatic breast cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE Drug: rhuMAb VEGF (Bevacizumab)
Study Arms  ICMJE Not Provided
Publications * Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9. Epub 2007 Aug 8. Erratum in: J Natl Cancer Inst. 2008 Jan 16;100(2):156. J Natl Cancer Inst. 2008 May 7;100(9):685.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE September 2002
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Written informed consent
  • Women >=18 years of age
  • Histologically confirmed carcinoma of the breast with metastatic disease that is currently progressing; in subjects who present with metastatic disease, cytologic confirmation is permissible
  • Prior administration of one or two conventional chemotherapy regimens for metastatic disease (Subjects who have had bone marrow or peripheral blood stem cell transplantation in association with chemotherapy are eligible for this study.) -OR-
  • No prior chemotherapy for metastatic disease if the subject received a regimen containing both an anthracycline (or anthracenedione) and a taxane as adjuvant therapy and if relapse occurred within 12 months of completing adjuvant chemotherapy
  • Prior administration of both an anthracycline (or anthracenedione) and a taxane in either the adjuvant or metastatic setting
  • Recovery from reversible toxicities of prior therapy
  • Bi-dimensionally measurable disease; at least one target lesion must be bi-dimensionally measurable and at least one target lesion must not have been biopsied recently; all target lesions must be >=2 cm in longest dimension
  • ECOG performance status of 0 or 1
  • Use of an effective means of contraception in women of childbearing potential
  • Life expectancy of >=3 months
  • Willingness and capability to be accessible for follow-up

Exclusion Criteria:

  • Pleural effusions or bone lesions as the only manifestations of the current metastatic breast cancer
  • Known HER2-positive status (either 3+ by immunohistochemistry or positive by FISH), as evaluated at the institution, unless the subject has previously relapsed following Herceptin(R) therapy. Subjects may not continue Herceptin therapy while enrolled in this trial.
  • Other primary malignancies (other than basal cell carcinoma of the skin or in situ cervical cancer) within the 5 years preceding Day 0
  • Prior radiotherapy to a measurable metastatic lesion(s) if it is to be used as the only lesion to measure response, unless the target lesion within the radiation field is actively progressing and radiotherapy was completed >=6 months prior to randomization
  • Radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for metastatic breast cancer within 21 days prior to Day 0
  • Use of bisphosphonates unless initiated at least 21 days before Day 0
  • Previous treatment with capecitabine
  • Previous treatment with rhuMAb VEGF
  • History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke; all subjects must have a baseline CT or MRI of the head.)
  • Serious, non-healing wound, ulcer, or bone fracture
  • Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations other than in the breast within 7 days prior to Day 0; placement of a vascular access device within 7 days prior to Day 0

    • Current or recent (within 10 days prior to Day 0) use of full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters; for subjects receiving warfarin, international normalized ratio [INR] of <1.5; appropriate use of heparin should be discussed with the Medical Monitor)
    • Chronic, daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory medications (of the kind known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
  • Presence of bleeding diathesis or coagulopathy
  • Active infection requiring parenteral antibiotics on Day 0
  • Pregnancy (positive pregnancy test) or lactation

    • Proteinuria at baseline or clinically significant impairment of renal function
  • Severe renal impairment (creatinine clearance <30 mL/min at baseline using the Cockcroft-Gault formula)
  • Known sensitivity to 5-FU
  • Lack of physical integrity of the upper gastrointestinal tract, known malabsorption or other significant disease of the stomach, small intestine, liver, or kidney that may adversely affect the pharmacokinetics of capecitabine
  • History of allergy to iodine-containing contrast that required treatment and that would prohibit use of CT scan with contrast
  • Screening clinical laboratory values: *ANC of <1500/uL; *Platelet count of <75,000/uL; *INR of >=1.5; *Total bilirubin of >1.5 times upper limit of normal; *AST or ALT >2.5 times the upper limit of normal (>5 times the upper limit of normal in subjects with known metastatic disease in the liver); *Serum creatinine of >2.0 mg/dL; *Hemoglobin of <9 gm/dL (may be transfused to maintain or exceed this level)
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
  • Current or recent (within 28 days prior to Day 0) participation in another experimental drug study
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00109239
Other Study ID Numbers  ICMJE AVF2119g
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Genentech, Inc.
Study Sponsor  ICMJE Genentech, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Genentech, Inc.
Verification Date June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP